Ogenx Therapeutics ^Company

Ogenx Therapeutics Corporation is a clinical stage drug development company dedicated to advancing our platform of 35 Redoxagens for the treatment of numerous disease targets. The Redoxagens are designed to hack into redox-mediated ondrial signaling pathways to turn on cellular self-repair mechanisms. They differ from the regular drugs: instead of targeting a single xenobiotic mechanism, Redoxagens induce multitude of redox-mediated cellular self-repair signaling pathways in normal cells and cell death in cells with high reactive oxygen species (ROS) levels/severe oxidative stress (i.e. cancerous). ROS and ondrial substrates potentiate Redoxagens - making their action specific to redox sites of electron transport chain (ETC) inside ondria and plasma membrane redox system (PMRS) and cells with elevated ROS levels. Once they reach the redox process/ROS-rich environment Redoxagen API, Geroxane, is consumed producing ROS-burst after which redox activity returns to normal = no chronic toxicity. This results in a dual mode of action: a) in normal cells where redox activity is confined to ondria, activation of Redoxagens is triggered at PMRS or at ETC sites inside ondria and induces on redox-mediated ondrial and cellular self-repair signaling pathways b) in cancerous cells where energy production/redox activity is localized to the cytosol or in cells with severe oxidative stress where ROS concentration in cytosol is already high, activation of Redoxagens results in ROS burst in cytosol, which brings ROS concentration to toxic levels and triggers on cell death. Redoxagens have been tested in over 300 humans and over 8,000 horses against numerous diseases with profound success and without serious adverse events. Our principal focus is development of treatments for the Dry form of Age-related macular Degeneration. Our veterinary subsidiary Ogenx Animal Health is focused on development of treatments against Canine Lymphoma and Mast Cell Tumors and Equine Infectious Diseases.